A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Thymosin-beta-4 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms ARISE-2
- Sponsors ReGenTree
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting, according to a RegeneRx Biopharmaceuticals media release.
- 09 Nov 2016 According to a Regenex Pharmaceutical media release, company plans to complete and report patient data in in Q4 2017.
- 09 Nov 2016 Status changed from not yet recruiting to recruiting, as per RegeneRx Biopharmaceuticals media release.